Validation of SARS-CoV-2 (2019nCoV) codon-optimized (CO) Spike overexpression in HEK293 cell line by GeneMedi's adenoviral and lentiviral vector
Post Download

Figure. Validation of SARS-CoV-2 (2019nCoV) codon optimized (CO) Spike expression in HEK293 cell line by GeneMedi's adenoviral vector (GMV-V-2019nCoV-053, GMV-V-2019nCoV-047) and lentiviral vector (GMV-V-2019nCoV-051) with Immunofluorescence (left) and Western Blot (right) by FLAG antibody.
Collection of COVID-19 landscape knowledge base
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine
- A landscape for vaccine technology against infectious disease, COVID-19 and tumor.
COVID-19 landscape Knowledge Base
References
1. Wu, A. et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe, doi:10.1016/j.chom.2020.02.001 (2020).
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
